Advertisement

tolvaptan

You have accessRestricted Access
Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
Marie E. Edwards, Fouad T. Chebib, Maria V. Irazabal, Troy G. Ofstie, Lisa A. Bungum, Andrew J. Metzger, Sarah R. Senum, Marie C. Hogan, Ziad M. El-Zoghby, Timothy L. Kline, Peter C. Harris, Frank S. Czerwiec and Vicente E. Torres

CJASN August 2018, 13 (8) 1153-1161; DOI: https://doi.org/10.2215/CJN.01520218

Add to Selected Citations
Open Access
Burden of Proof for Tolvaptan in ADPKD
Reem A. Mustafa and Alan S.L. Yu

CJASN July 2018, 13 (7) 1107-1109; DOI: https://doi.org/10.2215/CJN.00190118

Add to Selected Citations
You have accessRestricted Access
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial
Vicente E. Torres, Eiji Higashihara, Olivier Devuyst, Arlene B. Chapman, Ronald T. Gansevoort, Jared J. Grantham, Ronald D. Perrone, John Ouyang, Jaime D. Blais and Frank S. Czerwiec

CJASN May 2016, 11 (5) 803-811; DOI: https://doi.org/10.2215/CJN.06300615

Add to Selected Citations
You have accessRestricted Access
Mild Chronic Hyponatremia in the Ambulatory Setting: Significance and Management
Helbert Rondon-Berrios and Tomas Berl

CJASN December 2015, 10 (12) 2268-2278; DOI: https://doi.org/10.2215/CJN.00170115

Add to Selected Citations